Continue to site >
Trending ETFs

Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$60.95

$2.31 B

0.00%

$0.00

0.85%

Vitals

YTD Return

5.5%

1 yr return

19.5%

3 Yr Avg Return

11.5%

5 Yr Avg Return

15.9%

Net Assets

$2.31 B

Holdings in Top 10

41.1%

52 WEEK LOW AND HIGH

$60.8
$53.44
$68.95

Expenses

OPERATING FEES

Expense Ratio 0.85%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 45.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$0

IRA

N/A


Fund Classification

Fund Type

Open End Mutual Fund

Investment Style

Health


Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

$60.95

$2.31 B

0.00%

$0.00

0.85%

PHSZX - Profile

Distributions

  • YTD Total Return 5.5%
  • 3 Yr Annualized Total Return 11.5%
  • 5 Yr Annualized Total Return 15.9%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.29%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    PGIM Jennison Health Sciences Fund
  • Fund Family Name
    PGIM Funds (Prudential)
  • Inception Date
    Jun 30, 1999
  • Shares Outstanding
    N/A
  • Share Class
    Inst
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    David Chan

Fund Description

The fund seeks investments whose prices will increase over time. It normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.


PHSZX - Performance

Return Ranking - Trailing

Period PHSZX Return Category Return Low Category Return High Rank in Category (%)
YTD 5.5% -80.1% 25.3% 67.29%
1 Yr 19.5% -28.4% 77.3% 41.21%
3 Yr 11.5%* -0.1% 33.4% 59.46%
5 Yr 15.9%* 2.1% 32.2% 16.08%
10 Yr 19.6%* 9.8% 21.9% 11.29%

* Annualized

Return Ranking - Calendar

Period PHSZX Return Category Return Low Category Return High Rank in Category (%)
2020 17.7% -13.6% 178.2% 32.95%
2019 15.2% 3.8% 63.8% 80.00%
2018 -13.5% -49.7% 21.5% 81.02%
2017 25.8% -59.8% 54.4% 20.74%
2016 -17.2% -36.6% 11.6% 64.06%

Total Return Ranking - Trailing

Period PHSZX Return Category Return Low Category Return High Rank in Category (%)
YTD 5.5% -80.1% 25.3% 67.29%
1 Yr 19.5% -30.4% 77.3% 38.74%
3 Yr 11.5%* -15.9% 33.4% 55.87%
5 Yr 15.9%* -7.4% 32.2% 13.79%
10 Yr 19.6%* 9.8% 21.9% 10.45%

* Annualized

Total Return Ranking - Calendar

Period PHSZX Return Category Return Low Category Return High Rank in Category (%)
2020 17.7% -13.6% 178.2% 32.95%
2019 15.2% 3.8% 63.8% 80.00%
2018 -13.5% -25.3% 22.2% 82.48%
2017 25.8% -10.8% 54.4% 22.22%
2016 -17.2% -36.6% 11.6% 73.44%

NAV & Total Return History


PHSZX - Holdings

Concentration Analysis

PHSZX Category Low Category High PHSZX % Rank
Net Assets 2.31 B 238 K 50.5 B 24.29%
Number of Holdings 87 11 477 41.77%
Net Assets in Top 10 943 M 2.18 K 21.1 B 17.72%
Weighting of Top 10 41.05% 8.6% 94.7% 41.77%

Top 10 Holdings

  1. UnitedHealth Group Inc 6.92%
  2. Humana Inc 5.64%
  3. Eli Lilly and Co 5.27%
  4. Immunomedics Inc 4.95%
  5. Danaher Corp 4.56%
  6. Thermo Fisher Scientific Inc 4.33%
  7. Natera Inc 3.43%
  8. Apellis Pharmaceuticals Inc 3.21%
  9. AbbVie Inc 3.17%
  10. Becton, Dickinson and Co 3.10%

Asset Allocation

Weighting Return Low Return High PHSZX % Rank
Stocks
98.12% 83.68% 101.79% 70.89%
Other
1.40% -24.25% 7.97% 9.70%
Cash
0.46% -0.82% 10.99% 49.79%
Preferred Stocks
0.03% 0.00% 6.25% 8.44%
Convertible Bonds
0.00% 0.00% 0.10% 17.30%
Bonds
0.00% 0.00% 15.36% 20.68%

Stock Sector Breakdown

Weighting Return Low Return High PHSZX % Rank
Healthcare
98.40% 63.33% 100.00% 79.32%
Basic Materials
1.60% 0.00% 8.13% 9.70%
Utilities
0.00% 0.00% 1.14% 17.30%
Technology
0.00% 0.00% 19.13% 23.63%
Real Estate
0.00% 0.00% 6.13% 21.10%
Industrials
0.00% 0.00% 7.02% 22.78%
Financial Services
0.00% 0.00% 1.92% 37.55%
Energy
0.00% 0.00% 0.80% 17.30%
Communication Services
0.00% 0.00% 7.81% 19.41%
Consumer Defense
0.00% 0.00% 28.21% 24.89%
Consumer Cyclical
0.00% 0.00% 16.95% 25.32%

Stock Geographic Breakdown

Weighting Return Low Return High PHSZX % Rank
US
85.20% 57.23% 100.70% 58.65%
Non US
12.92% 0.00% 42.77% 42.19%

PHSZX - Expenses

Operational Fees

PHSZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.85% 0.08% 2.91% 38.03%
Management Fee 0.73% 0.00% 1.25% 60.89%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

PHSZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

PHSZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PHSZX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 45.00% 0.00% 256.00% 50.91%

PHSZX - Distributions

Dividend Yield Analysis

PHSZX Category Low Category High PHSZX % Rank
Dividend Yield 0.00% 0.00% 2.44% 28.15%

Dividend Distribution Analysis

PHSZX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Monthly Monthly

Net Income Ratio Analysis

PHSZX Category Low Category High PHSZX % Rank
Net Income Ratio -0.29% -2.54% 1.92% 64.94%

Capital Gain Distribution Analysis

PHSZX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually

Dividend Payout History

View More +

PHSZX - Fund Manager Analysis

Managers

David Chan


Start Date

Tenure

Tenure Rank

Jun 30, 1999

22.27

22.3%

David Chan, CFA, is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Mr. Chan joined Jennison Associates in May 1992. He was previously with the Boston Consulting Group, where he was a team leader and consultant on projects in a wide variety of industries, but with a special focus in the health care area. Mr. Chan has also worked in various positions in the film and television industry. He received a BA in biochemistry from Harvard University and an MBA from Columbia University.

Debra Netschert


Start Date

Tenure

Tenure Rank

Jan 28, 2015

6.68

6.7%

Debra Netschert is a Managing Director and a Health Sciences Equity Portfolio Manager and Research Analyst of Jennison. Ms. Netschert joined Jennison Associates in January 2008. Prior to Jennison, Ms. Netschert worked at Magnetar Capital where she was a senior analyst responsible for health care coverage with an emphasis on biotechnology and pharmaceutical industries. Prior to her experience at Magnetar Capital, Ms. Netschert worked at Amaranth Advisors as a biotechnology analyst. From 2002 to 2004, she was vice president and senior analyst for biotechnology at Lazard Capital Markets. Ms. Netschert began her research career as an associate biotechnology analyst at UBS in 2000. She received her BS and MS from Boston University.

Daniel Matviyenko


Start Date

Tenure

Tenure Rank

Dec 15, 2020

0.79

0.8%

Daniel joined Jennison in December 2020 as a Managing Director and co-Portfolio Manager of Health Sciences strategies. Before joining Jennison, he was founder, chief investment officer, and portfolio manager at Malleus Capital. Prior to founding Malleus, Dan was a portfolio manager, managing director, and partner at Tudor Investment. Before joining Tudor, he was a portfolio manager and an executive director at UBS O’Connor. Earlier in his career, Dan held various roles as an equity analyst at a number of firms. Dan holds a BS in finance from the University of Connecticut.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.03 24.06 6.71 1.46